Study of FG-M131 for patients with certain types of T-cell lymphoma
This study tests an investigational drug called FG-M131 in patients with T-cell lymphoma that has come back or not responded to previous treatments. The goal is to see if it is safe and effective and to find the best dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of lymphoma called peripheral T-cell lymphoma or cutaneous T-cell lymphoma.
- Your lymphoma has come back or not responded to at least one previous treatment.
- You are able to provide a tumor tissue sample from a biopsy.
- You are in generally good health (able to do daily activities) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called TGRX-814 for people with certain blood cancers like non-Hodgkin's lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, or myelodysplastic syndromes. It aims to see if the drug is safe and effective.
This trial tests a medicine called MBS303 to see how safe it is and how well it works in adults with B-cell non-Hodgkin lymphoma (NHL) that has come back or did not respond to prior anti-CD20 treatment. It may help people who have few or no treatment options expected to improve survival.
This trial tests a new injection, MTM-H-001, in adults whose B-cell lymphoma has returned or not responded after at least two prior treatments. The goal is to see if it can help control the cancer.
This trial tests whether the experimental drug TC011 can help adults with a type of B-cell lymphoma that has come back or stopped responding after at least two rounds of chemotherapy. The study checks for safety and whether the treatment can shrink tumors.
This Phase 1/2 trial tests CRC01, a lab-made immune cell therapy, for adults whose lymphoma or B-cell leukemia has come back or did not respond to treatment. If you qualify, the study aims to see how safe CRC01 is and whether it can shrink tumors and improve outcomes.
This trial tests a new drug called BG-C137 for people with advanced solid tumors that have stopped responding to other treatments. The drug targets a protein called FGFR2b found on some cancer cells, aiming to deliver a therapy directly to the tumor.
Hear when a new PTCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.